Eli Lilly gets Alzheimer's drug approved in the US

Kisunla is a treatment for the early symptoms of the degenerative disease.
Studies have found that the new drug slows down the progression of Alzheimer's. | Photo: Mike Blake/Reuters/Ritzau Scanpix
Studies have found that the new drug slows down the progression of Alzheimer's. | Photo: Mike Blake/Reuters/Ritzau Scanpix
AF MARKETWIRE

Eli Lilly received approval from the US health authorities for a drug to treat early symptoms of Alzheimer’s disease on Tuesday, a company announcement states.

The new drug, Kisunla, has been shown in studies to slow down the progression of the dreaded disease.

After this approval, two Alzheimer’s treatments are now available to the approximately 6 million Americans affected by the disease. The second drug is Leqembi from the pharmaceutical company Eisai.

In a Phase III study, Kisunla showed a slowing effect on the progression of Alzheimer’s, reducing the decline in cognitive abilities and other functions by 35% over a period of 18 months compared to placebo.

In addition, patients who received the drug experienced a 39% reduction in the risk of the disease progressing to the next, more severe stage.

Eli Lilly shares fell 1.3% on Tuesday, but were previously down 3.9% when US President Joe Biden criticized both Eli Lilly’s and Novo Nordisk’s pricing of the highly popular obesity drugs Wegovy and Mounjaro in a joint post with Senator Bernie Sanders in USA Today. 

English edit: Catherine Brett

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Mike Blake/Reuters/Ritzau Scanpix

Gilead Sciences CMO to leave early 2025

For subscribers

Further reading